)
Edge20 Feb 2026
Dollar General: The Rural Retailer Playbook
How Dollar General built a small-box empire across rural America, scaling value and convenience into one of retail's most durable business models.
Spruce Biosciences
Spruce Biosciences (SPRB) investor relations material
Spruce Biosciences Oppenheimer 36th Annual Healthcare Life Sciences Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Oppenheimer 36th Annual Healthcare Life Sciences Conference summary25 Feb, 2026
Regulatory and clinical development
TA-ERT, an enzyme replacement therapy for MPS IIIB, is advancing toward FDA approval with a BLA submission planned for Q4 2024 and potential approval by mid-2027.
FDA has accepted heparan sulfate as a surrogate endpoint for accelerated approval, following consensus at a 2024 Reagan-Udall Foundation forum.
The agency has shown flexibility on CMC requirements, allowing staggered PPQ batch submissions, and maintains a stable, collaborative review team.
Long-term data show durable reductions in heparan sulfate and strong clinical benefits in cognition and adaptive behavior, especially when treatment starts early.
A confirmatory trial using cognitive endpoints is planned to run during regulatory review.
Market opportunity and commercialization
The MPS IIIB market is characterized by high unmet need, strong patient advocacy, and centralized care at specialized centers.
TA-ERT is expected to be well-tolerated and easier to administer than existing ICV therapies, with no hypersensitivity reactions observed.
Peak sales potential is estimated at over $1 billion, supported by improved diagnosis and extended patient survival.
Commercialization will focus on a targeted U.S. sales force and patient support hub, with potential for direct European launch and partnerships in Asia.
The company is open to expanding its rare disease portfolio to leverage its commercial infrastructure.
Financial position and milestones
Cash runway extends into early 2027, with a $50 million debt facility (of which $15 million drawn) and additional tranches tied to milestones.
Potential monetization of a priority review voucher could yield $100–$150 million.
Exploring non-dilutive capital through regional partnerships, especially in Asia.
Key 2026 milestones include BLA submission, manufacturing scale-up, and initiation of the confirmatory trial.
Additional pipeline asset for CAH (a monoclonal CRH ligand) may enter development this year.
Differentiate Spruce's HS-NRE data from REGENXBIO CRL
Detail the strategy for reaching $1B peak sales
Outline specific plans to bridge the cash runway gap
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Spruce Biosciences earnings date
Q4 202513 Mar, 2026
Spruce Biosciences
Next Spruce Biosciences earnings date
Q4 202513 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Spruce Biosciences Inc. is a biopharmaceutical company developing and commercializing therapies for rare endocrine disorders. The company's leading product candidate, tildacerfont, is a non-steroidal therapy designed to improve disease control and reduce steroid dependency in patients suffering from congenital adrenal hyperplasia (CAH). Tildacerfont is under clinical trial for both adult and pediatric classic CAH, as well as for females with polycystic ovary syndrome in a separateclinical trial. Spruce Biosciences has entered into strategic partnerships, including a license agreement with Eli Lilly and Company for research, development, and commercialization of compounds, and a collaboration and license agreement with Kaken Pharmaceutical for the treatment of CAH in Japan. The company is headquartered in South San Francisco, California, and its shares are listed on the NASDAQ under the ticker symbol SPRB.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage